A study of GC203 TIL for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new treatment called GC203 TIL, which uses your own immune cells to fight advanced solid tumors. It's for people who have tried standard treatments and have a tumor that can be removed to create this therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid tumor that has been confirmed by a biopsy
- You are between 18 and 75 years old
- You have tried standard treatments that didn't work or stopped working
- You have at least one tumor that can be measured on scans
- You are in fairly good health, able to take care of yourself and expected to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental TIL therapy (GC203) for people with advanced solid tumors who have no more standard options. Doctors will take a piece of your tumor, make it into a personalized cell treatment, and give it back to try to fight the cancer.
This trial tests a treatment using your own immune cells (TILs) to fight advanced solid tumors. If you have a tumor that can be removed to make the TILs, and you've tried other treatments without success, you may be eligible.
This trial tests a new type of personalized cell therapy (TIL) for people with advanced solid tumors who have run out of standard treatment options. It aims to see if this approach can help shrink tumors.
This study tests a new treatment that uses your own immune cells, called TIL, to fight advanced solid tumors. It may be given alone or with another drug that helps the immune system attack cancer. The goal is to see if this treatment is safe and effective for people who have already tried other treatments.
This trial tests a new treatment called GC203 TIL, which uses your own immune cells (TILs) that have been gene-edited to fight pancreatic cancer. It is for people whose cancer has not responded to standard treatments and who are healthy enough to undergo this therapy.
This trial tests GC101 tumor-infiltrating lymphocytes (TILs), which are special immune cells collected from a tumor, grown in a lab, and given back to treat gastrointestinal cancers that have returned or spread. It may help your immune system better attack the cancer, especially when standard treatments have not worked.
Hear when a new Solid Tumors, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.